Glaukos (NYSE:GKOS) today said it completed its acquisition of Glaukos for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. Get the full story on our sister site, Drug Delivery Business.
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]
Avedro earlier this month priced its initial public offering, looking to raise approximately $70 million in gross proceeds. The Waltham, Mass.-based company said it plans to float 5 million shares at a price of $14 per share, with the potential to bring in a total of $70 million. The initial public offering also comes with a […]
Avedro has set the terms for its initial public offering, looking to raise between $70 million and $80 million in total. The Waltham, Mass.-based ophthalmic device company said it plans to float 5 million shares of its common stock at between $14 and $16 per share. The company said it also plans to grant a 30-day […]
Avedro has registered for an upcoming initial public offering, looking to bring in approximately $86.3 million, according to a recently posted SEC filing. The Waltham, Mass.-based company aims to list its common stock on the Nasdaq Global Market under the symbol “AVDR,” according to the filing. Avedro is an ophthalmic device and pharmaceutical company focused on […]
Venture capital firms invested more than $738 million during the second quarter of 2018, $1 million less than the first quarter of this year, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and CB Insights. There was a total of 61 deals during Q2, an increase from the 48 that the industry saw during Q1. […]